SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant selling pressure as news of a DOJ investigation and FDA's intent to crack down on "illegal copycat drugs" casts a shadow over its new oral semaglutide product, prompting intense community discussion between those highlighting legal and regulatory risks and others viewing the decline as a major buying opportunity.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending on news of its capital runway extension to an impressive $250 million Equity Line of Credit into 2028, igniting community speculation about a significant short squeeze and a repeat of its past multi-day parabolic rallies. Investors are closely watching the small float and high volume, with discussions split between explosive potential and sustainability concerns.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as its stock rebounds following the FDA's strong signal to crack down on illegal copycat GLP-1 drugs, directly impacting competitors like Hims & Hers who recently launched a cheaper Wegovy alternative. This regulatory stance is seen as a bullish catalyst for NVO's patented weight-loss treatments, shifting the community's focus from the company's conservative 2026 sales outlook and intense competition in the expanding obesity market.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing its first-ever adjusted operating profit and celebrating 100 million battery swaps, sparking bullish sentiment and calls for a significant rally among investors, though some remain frustrated by perceived stock price suppression.

WorldFinancial

WorldFinancial ($WLFI) is trending as it faces intensifying congressional scrutiny over a significant foreign investment and its application for a U.S. National Trust Bank Charter, igniting a polarized community debate between "scam" accusations and bullish anticipation of future utility and Real World Asset (RWA) integrations.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending as the Dow Jones Industrial Average hit a 50,000 milestone and saw a significant surge, with the community debating if this "boomer index" rally signals a genuine "melt-up" or a "blow-off top" amid a rotation away from tech-heavy sectors.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee (LKNCY) is trending as a major shareholder consolidated ownership, seen by the community as a strong vote of confidence and fueling speculation about an imminent uplisting, while the reported end of aggressive price wars with competitors like Cotti Coffee is expected to significantly boost profit margins and further accelerate its rapid global store expansion.

Liberty Global Ltd. engages in the provision of communications services. It offers broadband, video, and mobile communication solutions. It operates through the following segments: Sunrise, Telenet, VM Ireland, and Central and Other. The company was founded on July 27, 2022, and is headquartered in Hamilton, Bermuda.

Liberty Global Ltd - Ordinary Shares - Class B

Liberty Global plc - Ordinary Shares - Class B

Liberty Global Class B shares are surging amid reports of its Nexfibre joint venture acquiring UK broadband network Netomnia, with community chatter also citing a Google Cloud AI partnership. This has fueled speculation about a low-float driven rally, drawing comparisons to other highly volatile Class B stocks.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is sharply lower after announcing a $22 billion charge to realign its EV strategy and suspending its 2026 dividend, sparking debate among investors who either see it as a painful but necessary reset or a signal of deeper troubles in the transitioning auto sector.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is surging following its FDA Breakthrough Device Designation for its CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation, coupled with promising early human study data for its cardiac catheter. The community is buzzing with high expectations for its 'game-changing' nanosecond PFA technology, citing its potential market disruption and short-squeeze dynamics from low float and substantial insider ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LPCN  $BIIB  Q4 earnings report is out. 

&quot;ZURZUVAE fourth quarter revenue of approximately$66.X million showed strong continued demand growth.&quot;

Congrats to Biogen and Supernus for their continued growth in this market, its nice to see.

Increasing revenue numbers can only help Lipocine with Supernus and Biogen doing the heavy lifting in gaining exposure while Lipocine completes their phase 3 trial. 

Lets hope topline results show the shorter treatment duration (48 hours vs 14 days), faster onset (hours vs days), impoved remission rate (up to 75%) and strong safety claims we&#39;ve seen in the trial updates all prove to be true. 

I can&#39;t believe Lipocine&#39;s entire market cap is still less than 1 quarter of Zurzuvae&#39;s revenue, that seems absurd to me at this point.
 https://investors.biogen.com/node/30141/html

Grace Peace

Inka

Kyle Peterson

Michelle1367

Eric Hernandez

Ben Tan

TrumDumGolfBumPondScum

Thomas Prindle

Aurian Zarrineh

Joe Stone

Christian

biib-20260206 SECURITIES AND EXCHANGE COMMISSION Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026 (Exact name of registrant as specified in its charter) (Address of principal executive offices; Zip Code) Registrant's telephone number, including area code: (Former name or former address, if changed since last report.)

Biogen

SEC Filing | Biogen

StockTwits For Android 

Lipocine Inc

Biogen Inc

  Q4 earnings report is out. 

"ZURZUVAE fourth quarter revenue of approximately$66.X million showed strong continued demand growth."

Congrats to Biogen and Supernus for their continued growth in this market, its nice to see.

Increasing revenue numbers can only help Lipocine with Supernus and Biogen doing the heavy lifting in gaining exposure while Lipocine completes their phase 3 trial. 

Lets hope topline results show the shorter treatment duration (48 hours vs 14 days), faster onset (hours vs days), impoved remission rate (up to 75%) and strong safety claims we've seen in the trial updates all prove to be true. 

I can't believe Lipocine's entire market cap is still less than 1 quarter of Zurzuvae's revenue, that seems absurd to me at this point.
 